In a groundbreaking exploration that challenges longstanding biological dogma, researchers have uncovered multifaceted roles for N-terminal formylmethionine (fMet) beyond its traditional identification as a bacterial signature. Historically recognized as a hallmark of bacterial and mitochondrial proteins, fMet is now emerging as a critical mediator in proteostasis, immune signaling, and stress adaptation, with profound physiological and pathological implications. This revelation not only reshapes our comprehension of molecular biology but also opens new therapeutic avenues for complex inflammatory and degenerative diseases.
Formyl peptides, distinguished by the presence of fMet at their N-terminus, were initially classified as pathogen-associated molecular patterns (PAMPs) due to their bacterial origin. The seminal discovery of formyl–Met–Leu–Phe (fMLF) as a potent neutrophil chemoattractant cemented the pivotal role of these peptides in immune surveillance. Binding with high affinity to the formyl peptide receptor 1 (FPR1), these molecules orchestrate neutrophil chemotaxis, degranulation, reactive oxygen species (ROS) generation, and phagocytosis. Intriguingly, formyl peptides activate FPR2 as well, a receptor with a broader ligand spectrum that modulates inflammatory responses contextually, either amplifying or dampening immune pathways.
Recent research shifts attention toward endogenous sources of formyl peptides, revealing them as damage-associated molecular patterns (DAMPs) during sterile inflammation. Unlike their bacterial counterparts, endogenous formyl peptides originate from mitochondrial stress, leakage, and cytosolic processes involving fMet-protein synthesis, the fMet-ribosome quality control (RQC) pathway, and the fMet/N-degron pathway. These mechanisms facilitate surveillance and clearance of aberrant proteins, underscoring a sophisticated cellular system that maintains proteome integrity under stress conditions.
Strikingly, under cellular stresses such as cold exposure or nutrient deprivation, mitochondria-targeted formyltransferases accumulate in the cytosol, initiating fMet-tRNAi synthesis independent of the mitochondrial compartment. This leads to synthesis of fMet-bearing nascent polypeptides in the cytosol, a phenomenon previously unappreciated in eukaryotic cells. These cytosolic fMet-tagged proteins undergo stringent quality control through pathways homologous to yeast RQC and the fMet/N-degron system in mammals, ensuring aberrant or misfolded proteins are efficiently degraded.
The dual identity of formyl peptides as both PAMPs and DAMPs signifies a convergence of microbial recognition and intrinsic cellular stress responses. This intersection accentuates the sophisticated balance in immune homeostasis, where formyl peptides serve as frontline messengers of danger irrespective of the source. Activation of FPR1 and FPR2 by these peptides kicks off cascades that mobilize the innate immune system, not only confronting infections but also modulating sterile inflammations integral to tissue repair and remodeling.
Beyond immune activation, formylmethionine’s role extends deeply into proteostasis—the regulation of protein synthesis, folding, and degradation. Cytosolic fMet incorporation influences nascent chain stability, interferes with essential N-terminal modifications, and disrupts proper targeting to organelles or membranes. These alterations reverberate through cellular metabolism, potentially exacerbating aggregation-prone states linked to neurodegeneration and aging.
Mitochondrial health also interlaces with formylmethionine signaling pathways. The delicate orchestration of oxidative phosphorylation and maintenance of the mitochondrial proton gradient appear susceptible to modulation by fMet-driven processes. Emerging evidence suggests that fMet dynamics in mitochondria may influence bioenergetic efficiency, implicating these pathways in metabolic diseases and age-associated mitochondrial decline.
Intriguingly, the fMet system plays a role in environmental adaptation. In poikilothermic organisms and peripheral body tissues subjected to cold stress, formylmethionine-associated pathways may facilitate adaptive responses enabling survival under fluctuating thermal conditions. This adaptive facet hints at evolutionary conserved mechanisms integrating metabolic and immune responses to environmental challenges.
Extending beyond homeostasis and immunity, cytosolic fMet pathways demonstrate a notable influence in cancer biology. Studies report that N-terminal fMet modifications suppress cancer cell proliferation and stemness-like traits, such as those governed by the transcription factors SOX2 and CD24. This intersection suggests potential for novel anti-cancer strategies targeting fMet modulation, leveraging its capacity to impair tumor growth and stem cell maintenance.
Clinical correlations bring urgency to understanding formylmethionine dynamics. Circulating fMet levels surge dramatically in acute inflammatory conditions, most notably septic shock, where concentrations align closely with disease severity and mortality. Remarkably, these elevations surpass those observed in uncomplicated bacteremia, implicating endogenous sources and host-mediated production of fMet in inflammatory pathology.
Elevated fMet levels also associate with chronic and autoimmune diseases including hypertension, severe COVID-19, systemic sclerosis, vasculitis, and rheumatoid arthritis. Across these disorders, mounting evidence underscores fMet’s role in neutrophil activation and perpetuation of inflammatory cascades, suggesting it as a central player in the pathological inflammation characteristic of these conditions.
Population-scale studies fortify the link between mitochondrial dysfunction, elevated systemic fMet, and age-related pathologies. Individuals exhibiting high circulating fMet display impaired mitochondrial translation fidelity, increased proteostatic stress, and a propensity toward degenerative diseases. Moreover, heightened fMet correlates with increased all-cause mortality, emphasizing its potential as a prognostic biomarker and therapeutic target.
Neutralization of pathogenic formyl peptides emerges as a promising therapeutic strategy. Innovative approaches employing immobilized anti-formyl peptide antibodies have demonstrated restoration of neutrophil function in sepsis models, effectively mitigating immune paralysis. Concurrent development of peptide-specific and pan-reactive anti-fMet antibodies further underscores the translational potential to combat inflammatory diseases by modulating this pathway.
Nevertheless, the scarcity of intact fMLF in physiological contexts poses a challenge, highlighting a critical need to pivot research toward endogenous, stress-responsive formyl peptides. Advancing detection methods and antibody specificity will be pivotal in unraveling the complex biology of these signals and unlocking targeted interventions.
Altogether, the paradigm shift acknowledging N-terminal formylmethionine as both a degron—a signal for protein degradation—and a critical mediator in immune and cellular stress pathways recalibrates our understanding of intracellular quality control and intercellular communication. This nexus between microbial mimicry, endogenous signaling, and disease pathogenesis heralds a new frontier in biomedical research with unparalleled potential for innovative diagnostics and therapeutics.
As this story unfolds, the intertwining of fMet signaling pathways with foundational cellular processes offers a fertile ground for discovery. With continuing advances, harnessing the biological nuances of formylmethionine will likely revolutionize how we diagnose, manage, and treat a spectrum of conditions from infection and inflammation to cancer and metabolic diseases, ushering in an era where molecular signals at the protein’s genesis dictate health and disease trajectories.
Subject of Research: N-terminal formylmethionine’s role in proteostasis, immune signaling, and stress adaptation.
Article Title: N-terminal formylmethionine as a degron and a specific signal in proteostasis and stress adaptation.
Article References:
Lee, CS., Kim, D. & Hwang, CS. N-terminal formylmethionine as a degron and a specific signal in proteostasis and stress adaptation. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01723-1
Image Credits: AI Generated
DOI: 08 May 2026
